Sign in
Active, not recruitingPhase 3

Neostigmine and Glycopyrrolate by Iontophoresis

Key facts

Who runs it
James J. Peters Veterans Affairs Medical Center
Where
The Bronx, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
6 people enrolled
Started
6 Nov 2020
Ended
1 Jan 2025
Type of study
Interventional
Treatments tested
  • Combination of Neostigmine and Glycopyrrolate
  • I-Box by Dynatronics
Record updated
8 April 2024

Who can take part

Age
18 years to 89 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (25)Hide the full registry criteria

Who can take part

  • Male or female
  • Age 18 to 89
  • Chronic SCI (>1 year post injury)
  • You have documented constipation/difficulty with bowel evacuation and/or experience pain, straining, or fecal incontinence

Who cannot take part

  • Previous adverse reaction or hypersensitivity to electrical stimulation
  • Known sensitivity (prior reaction or allergy) to neostigmine or glycopyrrolate
  • Concurrent illness (with or without fever), such as lower respiratory illnesses, increased mucous/secretin production, congestive heart failure (CHF), or pneumonia
  • Currently taking cholinesterase inhibitors, such as those for Parkinson's Disease (PD) or dementia (rivastigmine, donepezil etc.), or medication with anticholinergic activity, such as anti-depressants
  • Concurrent participation in a research study
  • History of mechanical obstruction (physical blockage) of the GI or urinary tract (e.g., due to scar tissues forming after surgery, gallstones)
  • Myocardial infarction (heart attack) within 6 months of trial
  • Malignant and/or uncontrollable hypertension (high blood pressure), defined as a blood pressure reading of 160/100 mmHg or higher with or without taking 3 or more different classes of anti-hypertensive medications (drugs used to treat high blood pressure)
  • Organ damage (heart \& kidney) and/or transient ischemic attack/cerebrovascular accident (TIA-CVA, or stroke) as a result of hypertension
  • Known past history of coronary artery disease or bradyarrhythmia (slow heart rate)
  • Inability to provide informed consent determined by Montreal Cognitive Assessment Test (MoCA) score of 20 or less. This test is used to detect mild cognitive impairment
  • History of ingrown hair folliculitis (inflammation of hair follicles)
  • Chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome with constipation (IBS-C), or other causes of difficulty with stool evacuation such as hypothyroidism (underactive thyroid)
  • Fever (as an isolated symptom without "illness"), or who may be exposed to high environmental temperatures
  • Currently taking the following medications: Bethanechol, Chloroquine, Colistin, Penicillamine, Lithium, Methylcellulose, Trimeprazine, Verapamil, Phenothiazines, Sparfloxacin, Amitriptyline, Doxepin, Imipramine, Potassium chloride, Saquinavir, Dronedarone, Cisapride, Bepridil, Terfenadine, Amiodarone, Ziprasidone, or any medication(s) that could result in adverse reactions with neostigmine and/or glycopyrrolate, as determined by a study physician
  • EKG abnormalities such as bradycardia, prolonged QTc interval, axis shift, bundle branch block, Wolff-Parkinson-White Syndrome (WPW syndrome), 2nd and 3rd degree heart blocks etc. (determined at screening 12-lead EKG)
  • Symptomatic orthostatic hypotension (low blood pressure with possible dizziness/fainting)
  • Deep brain stimulation
  • Pregnancy (women who are sexually active and of childbearing potential must utilize a method of contraception and agree to maintain a contraceptive method until completion of the study)
  • Lactating, nursing females
  • Myasthenia gravis

Where in United States

  • James J. Peters Veterans Affairs Medical CenterThe Bronx, United States

About the trial

What the trial wants to find out

To determine a lower effective dose of neostigmine to induce bowel evacuation by transcutaneous administration by iontophoresis.

The group in the trial

  • PrimaryTreatment being tested

    Subjects will receive medication administration intravenously, then through a wired ION system of NEO + GEO.

    Treatment: Combination of Neostigmine and Glycopyrrolate and I-Box by Dynatronics

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neostigmine and Glycopyrrolate by Iontophoresis to Induce Bowel Evacuation
Record updated
8 April 2024